KalVista Pharmaceuticals (STU:4XC1) Total Equity : €81.32 Mil (As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Total Equity?

KalVista Pharmaceuticals's total equity for the quarter that ended in Jan. 2024 was €81.32 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

KalVista Pharmaceuticals Total Equity Historical Data

The historical data trend for KalVista Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Total Equity Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Total Equity

Get a 7-Day Free Trial

86.10

77.05

215.01

171.40

146.86

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Equity	Get a 7-Day Free Trial															171.16	146.86	125.96	108.38	81.32

KalVista Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

KalVista Pharmaceuticals's Total Equity for the fiscal year that ended in Apr. 2023 is calculated as

Total Equity	=	Total Assets(Q: Apr. 2023 )	-	Total Liabilities(Q: Apr. 2023 )
	=	167.08	-	20.225
	=	146.86

KalVista Pharmaceuticals's Total Equity for the quarter that ended in Jan. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jan. 2024 )	-	Total Liabilities(Q: Jan. 2024 )
	=	104.623	-	23.303
	=	81.32

KalVista Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines